Identification of Small-Molecule Frequent Hitters from AlphaScreen High-Throughput Screens

Although small-molecule drug discovery efforts have focused largely on enzyme, receptor, and ion-channel targets, there has been an increase in such activities to search for protein-protein interaction (PPI) disruptors by applying high-throughout screening (HTS)–compatible protein-binding assays. However, a disadvantage of these assays is that many primary hits are frequent hitters regardless of the PPI being investigated. We have used the AlphaScreen technology to screen four different robust PPI assays each against 25,000 compounds. These activities led to the identification of 137 compounds that demonstrated repeated activity in all PPI assays. These compounds were subsequently evaluated in two AlphaScreen counter assays, leading to classification of compounds that either interfered with the AlphaScreen chemistry (60 compounds) or prevented the binding of the protein His-tag moiety to nickel chelate (Ni2+-NTA) beads of the AlphaScreen detection system (77 compounds). To further triage the 137 frequent hitters, we subsequently confirmed by a time-resolved fluorescence resonance energy transfer assay that most of these compounds were only frequent hitters in AlphaScreen assays. A chemoinformatics analysis of the apparent hits provided details of the compounds that can be flagged as frequent hitters of the AlphaScreen technology, and these data have broad applicability for users of these detection technologies.

[1]  Olivier Sperandio,et al.  Rationalizing the chemical space of protein-protein interaction inhibitors. , 2010, Drug discovery today.

[2]  Crystal and electronic structure of heteromolecular complexes of 3,6-bis(3,5-dymethylpyrazole-1-yl)-1,2,4,5-tetrazine with azoles , 2013, Journal of Structural Chemistry.

[3]  Igor V. Tetko,et al.  ToxAlerts: A Web Server of Structural Alerts for Toxic Chemicals and Compounds with Potential Adverse Reactions , 2012, J. Chem. Inf. Model..

[4]  E. Constable,et al.  Functionalised 3,3′-bipyridines—a new class of dinucleating ligands , 1998 .

[5]  Ilya Kagan,et al.  Between a Rock and a Hard Place , 2016, Journal of the American Psychiatric Nurses Association.

[6]  Philip Gribbon,et al.  Exemplification of the challenges associated with utilising fluorescence intensity based assays in discovery , 2010, Expert opinion on drug discovery.

[7]  Stefan Wetzel,et al.  Interactive exploration of chemical space with Scaffold Hunter. , 2009, Nature chemical biology.

[8]  Igor V. Tetko,et al.  Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices , 2001, J. Chem. Inf. Comput. Sci..

[9]  A G Cochran,et al.  Antagonists of protein-protein interactions. , 2000, Chemistry & biology.

[10]  E. Zangrando,et al.  1-(2-Picolyl)-substituted 1,2,3-triazole as novel chelating ligand for the preparation of ruthenium complexes with potential anticancer activity. , 2011, Dalton transactions.

[11]  J. Matthews,et al.  Protein-protein interactions in human disease. , 2005, Current opinion in structural biology.

[12]  N M Green,et al.  Avidin and streptavidin. , 1990, Methods in enzymology.

[13]  J. Baell,et al.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.

[14]  John P. Overington,et al.  How many drug targets are there? , 2006, Nature Reviews Drug Discovery.

[15]  Christopher L. McClendon,et al.  Reaching for high-hanging fruit in drug discovery at protein–protein interfaces , 2007, Nature.

[16]  W. Kaim.  The coordination chemistry of 1,2,4,5-tetrazines , 2002 .

[17]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[18]  I. Tetko,et al.  ISIDA - Platform for Virtual Screening Based on Fragment and Pharmacophoric Descriptors , 2008 .

[19]  M. Willander,et al.  Analysis of biomolecules using surface plasmons. , 2009, Methods in molecular biology.

[20]  Igor V. Tetko,et al.  Online chemical modeling environment (OCHEM): web platform for data storage, model development and publishing of chemical information , 2011, J. Comput. Aided Mol. Des..

[21]  Igor V. Tetko,et al.  Development of Dimethyl Sulfoxide Solubility Models Using 163 000 Molecules: Using a Domain Applicability Metric to Select More Reliable Predictions , 2013, J. Chem. Inf. Model..

[22]  Yun Zhao,et al.  An 2-(2'-aminophenyl)benzoxazole-based OFF-ON fluorescent chemosensor for Zn2+ in aqueous solution. , 2011, Organic & biomolecular chemistry.

[23]  Seth M. Cohen,et al.  Chelator Fragment Libraries for Targeting Metalloproteinases , 2010, ChemMedChem.

[24]  Dieter Braun,et al.  Molecular interaction studies using microscale thermophoresis. , 2011, Assay and drug development technologies.

[25]  Giovanna Zinzalla,et al.  Targeting protein-protein interactions for therapeutic intervention: a challenge for the future. , 2009, Future medicinal chemistry.

[26]  Andrew C. Good,et al.  An Empirical Process for the Design of High-Throughput Screening Deck Filters , 2006, J. Chem. Inf. Model..

[27]  B. Collins,et al.  Applications of isothermal titration calorimetry in pure and applied research—survey of the literature from 2010 , 2012, Journal of molecular recognition : JMR.

[28]  I. Tetko,et al.  Applicability domain for in silico models to achieve accuracy of experimental measurements , 2010 .

[29]  D. Bojanic,et al.  Impact of high-throughput screening in biomedical research , 2011, Nature Reviews Drug Discovery.

[30]  Evan Bolton,et al.  PubChem's BioAssay Database , 2011, Nucleic Acids Res..

[31]  Kristin E. D. Coan,et al.  Stoichiometry and physical chemistry of promiscuous aggregate-based inhibitors. , 2008, Journal of the American Chemical Society.

[32]  M. Albrecht,et al.  8-Hydroxyquinolines in metallosupramolecular chemistry , 2008 .